Source
Conference Library
m622 Industry Conference — speaker/company/product/paper/quote cards (public fields only).
90 assets · provenance shown as-is · no ratings, no reviews.
Yingzhong Li (李英中) · Founder & President · SunVax mRNA Therapeutics Inc.
conferenceCapstan Therapeutics · in vivo CAR-T via LNP/mRNA (acquired by AbbVie)
conferenceEsoBiotec SA · Mont-Saint-Guibert, Belgium · ENaBL platform
conferenceImmuFron · MxV-G lentiviral vector platform
conferenceInterius BioTherapeutics · in vivo CAR-T (acquired by Kite/Gilead)
conferenceKelonia Therapeutics · KLN-1010 (per ASGCT 2025 abstracts)
conferenceOrbital Therapeutics · in vivo RNA delivery (acquired by BMS)
conferencePregene · Kite/Gilead deal $1.64B
conferenceSunVax mRNA Therapeutics Inc.
conferenceTessera Therapeutics · in vivo RNA / Gene Writing platform
conferenceUmoja Biopharma · VivoVec platform · UB-VV100 / UB-VV400
conferenceESO-T01 · in vivo BCMA CAR-T (EsoBiotec) · phase 1
conferenceKLN-1010 · Kelonia Therapeutics · per ASGCT 2025 abstracts
conferenceSV101 · mouse T cell LNP/mRNA delivery kit
conferenceSV102 · human T cell LNP/mRNA delivery kit
conferenceSV104 · human CD4 T cell LNP/mRNA delivery kit
conferenceSV105 · mouse CD8 T cell LNP/mRNA delivery kit
conferenceSV106 · human CD8 T cell LNP/mRNA delivery kit
conferenceSV108 · human NK cell LNP/mRNA delivery kit
conferenceSV110 · human monocyte/macrophage LNP/mRNA delivery kit
conferenceSV112 · lymphatic trafficking LNP/mRNA delivery kit
conferenceSV114 · human HSC LNP/mRNA delivery kit
conferenceSV116 · human B cell LNP/mRNA delivery kit
conferenceSVDNA · LNP DNA transfection kit
conferenceSVSP288 · 288-condition LNP screening plate
conferenceSVSP48 · 48-well LNP screening plate
conferenceUB-VV100 · Umoja Biopharma · in vivo CAR-T via VivoVec
conferenceUB-VV400 · Umoja Biopharma · in vivo NK cell (per OPORD-002 P1)
conferenceESO-T01 · 9 patients in vivo BCMA CAR-T · r/r multiple myeloma · CRS in 4/5
oncologyESO-T01 · CRS profile · vector-infusion-related toxicity distinct from ex vivo CAR-T
oncologyESO-T01 · feasibility signal · in vivo CAR-T generation in human
oncologyACS Nano 2026 · Spleen-Tropic LNP for in vivo CAR-T engineering · Guo/Li
oncologyBest Pract Res Clin Rheumatol 2026 · CAR-T 'Living drugs' in SLE · Khalili/Askanase
oncologyBone Marrow Transplant 2026 · Bridging therapy before anti-BCMA CAR-T · Rasche/Raab
oncologyCancers 2025 · Review: CAR therapies ex vivo and in vivo · biomimetic nanoparticles
oncologyComm Biology 2025 · CATP cascade amplification of therapeutic payloads · Yingzhong Li (SunVax · first/corresponding)
oncologyExp Hematol Oncol 2025 · Review: In vivo CAR-T cell engineering · concept, progress, challenges
oncologyEur J Haematol 2026 · Salvage therapy with BCMA TCE + pomalidomide · Di Palma-Grisi/Parmar
oncologyEsoBiotec 2024-12-11 PR · IIT initiation · ESO-T01 in China
oncologyCancer Immunol Res 2026 · FAP-CAR via targeted LNP · lymphodepletion-free in vivo · Bajbouj/Puré
oncologyInside Precision Medicine · 2026-03-27 · in vivo CAR-T toxicities review
oncologyJCO 2026 · Phase II BCMA CAR-T in NDMM (CAREMM-001) · ex vivo baseline
oncologyJ Controlled Release 2026 · DNA-directed multivalent LNP for T cell · Kelly/Kamat
oncologyJ Hematol Oncol 2026 · CAR-Macrophage review · Chen/Lin
oncologyLabiotech.eu · in vivo CAR-T momentum · AstraZeneca → EsoBiotec $1B
oncologyLancet 2025 · In-vivo BCMA CAR T-cell therapy for r/r MM (ESO-T01 companion)
oncologyMol Cancer 2026 · CAR-NK cell therapy review · Liu/Cao
oncologyNature Cancer 2021 · Multifunctional oncolytic nanoparticles · IL-12 saRNA · Yingzhong Li (MIT · first author · pre-SunVax)
oncologyPanel 1 Adrian · 'millions of doses per year potential'
conferenceBrandon (Mojo) · 'lentiviral manufacturing is where antibodies were 25-30 years ago'
conferencePanel 1 · 'LNPs can be very scalable, as already seen with COVID vaccines'
conferencePanel 1 moderator · 'So Brandon, how do we drive down the cost of goods'
conferencePanel 2 · TCE / sequencing / early lines (placeholder quote)
conferencePanel 3 · '9 patients all developed CAR-T cells in vivo · levels similar to ex vivo'
conferencePanel 3 · 'vector-infusion-related toxicity distinct from ex vivo CAR-T'
conferencePanel 4 · hybrid delivery / 5-10y outlook (placeholder quote)
conferenceYingzhong Li · SunVax platform overview at 5/16 dinner (paraphrase)
conferenceYingzhong Li · Q1 response · repeat-dosing immune effects (hedge)
conferenceYingzhong Li · Q2 response · Mouse vs Human LNP + PDX 92-94% caveat
conferenceYingzhong Li · Q3 response · Human cytokine validation roadmap
conferenceYingzhong Li · Q4 response · 5-step LNP discovery methodology
conferenceYingzhong Li · Q5 response · 'Yeah yeah yeah · Yes' confirming pure empiricism
conferenceTopic · 5-10 year commercialization outlook · in vivo cell therapy
conferenceTopic · big pharma in vivo CAR-T acquisition wave (2025)
conferenceTopic · cost of goods (CoG) · in vivo / lentiviral / LNP economics
conferenceTopic · early lines treatment selection · r/r MM
conferenceTopic · hybrid delivery (LNP + lentiviral combination) · 5-10y outlook
conferenceTopic · in vivo CAR-T safety distinction · vector-infusion vs ex vivo CRS
conferenceTopic · in vivo vs ex vivo CAR-T · feasibility / safety / sequencing
conferenceTopic · lentiviral manufacturing scalability · 25-30 year analogy + 1000x headroom
conferenceTopic · Repeat-dosing in vivo CAR-T / LNP delivery · highest-value missing dataset
conferenceTopic · TCE (T-cell engagers) sequencing · early lines in r/r MM
conferenceClaim · 2025 big pharma in vivo CAR-T acquisitions establish $350M-$2.1B valuation range
car-tClaim · EsoBiotec ENaBL lentiviral platform validated via $1B AstraZeneca acquisition
car-tClaim · in vivo CAR-T safety profile distinct from ex vivo CRS · vector-infusion-related toxicity
car-tClaim · in vivo BCMA CAR-T feasibility demonstrated in 9 r/r MM patients
car-tClaim · lentiviral/LNP manufacturing has 10-100x (potentially 1000x) headroom
car-tClaim · LNP manufacturing scalability proven via COVID vaccines
car-tClaim · LNP targeting moieties and lipid chemistry steer in vivo biodistribution · enabling cell-type-specific delivery
car-tClaim · Lymphodepletion-free in vivo CAR-T is now empirically demonstrated
car-tClaim · In vivo cell engineering extends beyond T cells · CAR-T + CAR-NK + CAR-M + B-cell lanes
car-tClaim · PDX 'mouse host' caveat is widely misunderstood across industry
car-tClaim · SunVax explicitly disclaims AI/ML usage · marketing constraint + honesty-signal
car-tClaim · SunVax SV-Delivery is complementary (not direct competitor) to therapeutic-developer in vivo CAR-T companies
car-tCapstan Therapeutics · LNP/mRNA in vivo CAR-T (acquired by AbbVie $2.1B)
conferenceEsoBiotec SA · ENaBL platform · ESO-T01 (acquired by AstraZeneca)
conferenceInterius BioTherapeutics · lentiviral in vivo CAR-T (acquired by Kite/Gilead $350M)
conferenceKelonia Therapeutics · KLN-1010 (per ASGCT 2025 abstracts)
conferenceOrbital Therapeutics · in vivo RNA delivery (acquired by BMS $1.5B)
conferenceUmoja Biopharma · VivoVec platform · UB-VV100 / UB-VV400 (independent · not acquired)
conference